AbbVie, SLB, Amphenol, And More On CNBC's 'Final Trades'

On CNBC's “Halftime Report Final Trades,” Jason Snipe, founder and chief investment officer of Odyssey Capital Advisors, said he likes AbbVie Inc. (NYSE:ABBV) and recommended staying long on the stock.

As per the recent news, AbbVie, on Jan. 12, announced a voluntary agreement with the Trump administration to advance access and affordability further. AbbVie said it will provide low prices in Medicaid while pledging $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade.

Shannon Saccocia, chief investment officer of NB Private Wealth, named iShares U.S. Healthcare ETF (NYSE:IYH) as her final trade.

Don't forget to check out our premarket coverage here

Stephanie Link, chief investment strategist, head of investment solutions and portfolio manager at Hightower Advisors, said SLB N.V. (NYSE:SLB) posted upbeat earnings and revenue for the latest quarter.

On Jan. 23, the company said fourth-quarter revenue totaled $9.745 billion, up 5% from a year earlier and above the $9.547 billion analyst estimate. Diluted GAAP earnings per share were 55 cents, down from 77 cents a year earlier, while diluted EPS, excluding charges and credits, was 78 cents, down from 92 cents a year earlier but ahead of the 74-cent estimate.

Joe Terranova, senior managing director for Virtus Investment Partners, picked Amphenol Corporation (NYSE:APH) as his final trade.

Lending support to his choice, JP Morgan analyst Samik Chatterjee, on Tuesday, maintained Amphenol with an Overweight rating and raised the price target from $160 to $185.

Price Action:

• AbbVie shares gained 1.4% to close at $223.93 on Tuesday.
• iShares U.S. Healthcare ETF fell 1.5% during the session.
• Amphenol shares gained 6.9% to close at $166.25 on Tuesday.
• SLB shares rose 1.9% to settle at $50.66.

Image: Shutterstock